These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26513826)

  • 1. [Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
    Kwon JH
    Korean J Gastroenterol; 2015 Aug; 66(2):131-3. PubMed ID: 26513826
    [No Abstract]   [Full Text] [Related]  

  • 2. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Shiha G; Esmat G; Hassany M; Soliman R; Elbasiony M; Fouad R; Elsharkawy A; Hammad R; Abdel-Razek W; Zakareya T; Kersey K; Massetto B; Osinusi A; Lu S; Brainard DM; McHutchison JG; Waked I; Doss W
    Gut; 2019 Apr; 68(4):721-728. PubMed ID: 29666174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
    Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
    J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):329. PubMed ID: 24776807
    [No Abstract]   [Full Text] [Related]  

  • 9. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Palecki J; Reddy KR
    Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
    Graf Einsiedel H; Christiansen H; Wiegand J
    Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
    [No Abstract]   [Full Text] [Related]  

  • 12. Shorter treatments for hepatitis C: another step forward?
    Foster GR
    Lancet; 2015 Mar; 385(9973):1054-5. PubMed ID: 25591504
    [No Abstract]   [Full Text] [Related]  

  • 13. EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM.
    Vashakidze E; Imnadze T; Mikadze I
    Georgian Med News; 2018 Jan; (274):112-116. PubMed ID: 29461238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M
    Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for hepatitis C--the costs of success.
    Hoofnagle JH; Sherker AH
    N Engl J Med; 2014 Apr; 370(16):1552-3. PubMed ID: 24725236
    [No Abstract]   [Full Text] [Related]  

  • 16. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Huysentruyt K; Stephenne X; Varma S; Scheers I; Leclercq G; Smets F; Sokal EM
    Liver Transpl; 2017 Apr; 23(4):552-553. PubMed ID: 28006874
    [No Abstract]   [Full Text] [Related]  

  • 17. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are we hopefully very close to the end of HCV?
    Tahan V
    Turk J Gastroenterol; 2014 Apr; 25(2):230-1. PubMed ID: 25003693
    [No Abstract]   [Full Text] [Related]  

  • 19. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
    Gentile I; Borgia G
    Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
    [No Abstract]   [Full Text] [Related]  

  • 20. Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    Øvrehus ALH; Krarup H; Birkemose I; Holm DK; Mössner B; Ernst A; Christensen PB
    J Hepatol; 2018 Apr; 68(4):840-842. PubMed ID: 29223370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.